Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC

NCT07126119 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Upper Tract Urothelial Carcinoma
Neoadjuvant Therapy
PD-1 Inhibitor
Nab-paclitaxel

Interventions

DRUG: Nab-Paclitaxel
DRUG: Tislelizumab
PROCEDURE: Radical nephroureterectomy (RNU)

Sponsor

Tianjin Medical University Second Hospital